Erin Darakjian - P3 Health VP Officer
| PIII Stock | USD 0.24 0.03 14.29% |
VP
Erin Darakjian is VP Officer of P3 Health Partners
| Address | 2370 Corporate Circle, Henderson, NV, United States, 89074 |
| Phone | 702 910 3950 |
| Web | https://p3hp.org |
Erin Darakjian Latest Insider Activity
Tracking and analyzing the buying and selling activities of Erin Darakjian against P3 Health stock is an integral part of due diligence when investing in P3 Health. Erin Darakjian insider activity provides valuable insight into whether P3 Health is net buyers or sellers over its current business cycle. Note, P3 Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell P3 Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Erin Darakjian over two weeks ago Acquisition by Erin Darakjian of 100000 shares of P3 Health subject to Rule 16b-3 | ||
Erin Darakjian over a year ago Acquisition by Erin Darakjian of 100000 shares of P3 Health subject to Rule 16b-3 |
P3 Health Management Efficiency
The company has return on total asset (ROA) of (0.1202) % which means that it has lost $0.1202 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4125) %, meaning that it created substantial loss on money invested by shareholders. P3 Health's management efficiency ratios could be used to measure how well P3 Health manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.31. The current Return On Capital Employed is estimated to decrease to -0.31. As of now, P3 Health's Debt To Assets are decreasing as compared to previous years.Similar Executives
| Found 7 records | VP Age | ||
| Brian JD | Acadia Healthcare | 54 | |
| Christopher Weigl | Select Medical Holdings | 40 | |
| Brian Farley | Acadia Healthcare | 54 | |
| Timothy Gertsch | agilon health | 37 | |
| Beverly Wittekind | The Ensign Group | 59 | |
| John Darby | Encompass Health Corp | 59 | |
| Tabitha Obenour | Sonida Senior Living | N/A | |
Management Performance
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.12 |
P3 Health Partners Leadership Team
Elected by the shareholders, the P3 Health's board of directors comprises two types of representatives: P3 Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PIII. The board's role is to monitor P3 Health's management team and ensure that shareholders' interests are well served. P3 Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, P3 Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BSN CRNI, Chief Staff | ||
| Leslie Fisher, General Affairs | ||
| Roy Youngblood, Director Compliance | ||
| Kassi APR, Culture Communications | ||
| Todd MHA, Chief Officer | ||
| James II, Chief Officer | ||
| FACEP FACP, CEO CoFounder | ||
| Erin Darakjian, VP Officer | ||
| William Bettermann, Executive COO | ||
| MD MBA, Chief CoFounder | ||
| Jessica Puathasnanon, General Officer | ||
| Devery Goodey, Senior Technology | ||
| Atul Kavthekar, Chief Officer | ||
| Karen Blomquist, Vice Relations | ||
| Lorie CPA, COO Chairwoman | ||
| Cheyenne Ross, VP Compliance | ||
| David Yarger, Market Market | ||
| Leif Pedersen, Chief Officer | ||
| Aric MD, CEO President |
PIII Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is P3 Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 116.24 M | ||||
| Shares Outstanding | 162.86 M | ||||
| Shares Owned By Insiders | 23.20 % | ||||
| Shares Owned By Institutions | 24.98 % | ||||
| Number Of Shares Shorted | 957.12 K | ||||
| Price To Book | 0.29 X |
Currently Active Assets on Macroaxis
When determining whether P3 Health Partners is a strong investment it is important to analyze P3 Health's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact P3 Health's future performance. For an informed investment choice regarding PIII Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in P3 Health Partners. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of P3 Health. If investors know PIII will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about P3 Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.86) | Revenue Per Share 11.552 | Quarterly Revenue Growth 0.152 | Return On Assets (0.12) | Return On Equity (0.41) |
The market value of P3 Health Partners is measured differently than its book value, which is the value of PIII that is recorded on the company's balance sheet. Investors also form their own opinion of P3 Health's value that differs from its market value or its book value, called intrinsic value, which is P3 Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because P3 Health's market value can be influenced by many factors that don't directly affect P3 Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between P3 Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if P3 Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, P3 Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.